ClinicalTrials.gg
TerminatedNCT04439409AVASNAUpdated Oct 27, 2023

Variability of the Autonomic Nervous System (ANS) During Cluster Headache (CH).

An observational study in Cluster Headache, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

Why this study was terminated
No inclusions for 2 years
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
19
Ages
18 Years and older
Sex
All
01

Study summary

Cluster Headache (CH) is associated with ipsilateral vegetative signs, related to parasympathetic system hyperactivity and/or signs of sympathetic hypoactivity. The precise mechanism of Cluster Headache (CH) is still unknown. The question is whether these dysautonomic disorders are simply secondary to the Cluster Headache (CH) process or whether they are the triggering factor.

Read the detailed description

This study cares about the evolution of the Autonomic Nervous System (ANS) in Cluster Headache (CH) seizures. Patients will be offered Holter ECG to study the temporal relationships between changes in Autonomic Nervous System (ANS) activity during Headache (CH) seizures and changes in Autonomic Nervous System (ANS) activity before and after seizure treatment, using heart rate variability measurement.

The hypothesis is that there would be an initial temporary sympathetic activation, followed quickly by parasympathetic hyperactivation and a return to a state of equilibrium.

02

Conditions studied

  • Cluster Headache

Keywords

  • Cluster Headache
  • Autonomic Nervous System
  • Seizure
  • Holter
  • Electrocardiogram
  • (LF/HF) ratio
  • Daytime seizure
  • Night seizure
03

In context

Cluster Headache

120 studies on the registry are indexed under Cluster Headache; 28 are open to participants now.

This study's enrollment of 19 is below the median of 70 across 31 observational studies indexed under Cluster Headache.

Browse Cluster Headache studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 597 studies on the registry; 127 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Cluster Headache (CH) will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years of age
  • Affiliated or entitled to a Social Security scheme
  • Resident in the territories of the hospital grouping of Loire territory (located less than 50 km away)
  • Whose diagnosis of episodic or chronic Cluster Headache (CH) has been confirmed according to International Classification of Headache Disorders (ICHD)- 3 criteria
  • With a regular sinus rhythm and heart rate

Exclusion criteria

Exclusion Criteria:

  • Conditions contraindicating the use of injectable sumatriptan
  • Conditions likely to affect the Autonomic Nervous System (ANS): dysautonomic sensory neuropathies, sleep apnea syndrome, etc.
  • Cognitive or language disorders that may interfere with pain assessment and seizure follow-up.
  • Patients taking treatments that may modify the Autonomic Nervous System (ANS): catecholamine (adrenaline, noradrenaline, dopamine), B-stimulants (isoprenaline, dobutamine, dopexamine, salbutamol, terbutaline, fenoterol, orciprenaline, clenbuterol, salmeterol, formoterol), B-blockers, alpha-stimulants (midodrine, alpha-methyl-dopa, clonidine, rilmenidine, moxonidine), alpha-blockers (phentolamine, prazosin, urapidil), amphetamine, tyramine, ephedrine, selegiline, cocaine, imipramine.
  • Impossibility to submit to the medical follow-up of the program for geographical, social or psychological reasons.
  • Patient deprived of liberty or under guardianship.
  • Patient with preventive background treatment of Cluster Headache (CH).
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
19 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with Cluster Headache (CH)

    Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.

    Device: Holter electrocardiogram

Interventions

  • DeviceHolter electrocardiogram

    Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.

06

What researchers measure

Primary outcomes

  1. Low Frequency/High Frequency (LF/HF) ratio at the onset of the first night seizure

    Comparison of the Low Frequency/High Frequency (LF/HF) ratio at the onset of the first night seizure during the basal period, pre-seizure, seizure and after the seizure.

    Time frame: Day: 7

Secondary outcomes

  1. Low Frequency/High Frequency (LF/HF) ratio at the onset of the first daytime seizure

    Comparison of the Low Frequency/High Frequency (LF/HF) ratio at the onset of the first daytime seizure during the basal period, pre-seizure, seizure and after the seizure.

    Time frame: Day: 7

  2. Low Frequency during daytime and night seizure

    Comparison of measure of Low Frequency during daytime and night seizure.

    Time frame: Day: 7

  3. High Frequency (HF) during daytime and night seizure

    Comparison of measure of High Frequency (HF) during daytime and night seizure.

    Time frame: Day: 7

  4. Correlation between several parameters

    Correlation between Heart Rate Variability (HRV), changes in the Low Frequency/High Frequency (LF/HF) ratio, the Low Frequency (LF) and the High Frequency (HF), and the intensity of pain measured on the Visual Analog Scale (VAS).

    Time frame: Day: 7

07

Study locations

1 site
  • CHU Saint-Etienne
    Saint-Etienne, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04439409
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Aug 19, 2020
Primary completion
Dec 7, 2021
Completion
Dec 15, 2021
Last update
Oct 27, 2023

Study contacts

Christelle CREAC'H, MD
principal investigator · Centre Hospitalier Universitaire de Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion